These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6722822)

  • 1. Flux of teniposide (VM-26) across the plasma membrane of teniposide-resistant sublines of L1210 cells.
    Lee T; Roberts D
    Cancer Res; 1984 Jul; 44(7):2986-90. PubMed ID: 6722822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection and characterization of L1210 sublines resistant to teniposide (VM-26).
    Lee T; Roberts D
    Cancer Res; 1984 Jul; 44(7):2981-5. PubMed ID: 6722821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expressions of resistance and cross-resistance in teniposide-resistant L1210 cells.
    Roberts D; Lee T; Parganas E; Wiggins L; Yalowich J; Ashmun R
    Cancer Chemother Pharmacol; 1987; 19(2):123-30. PubMed ID: 3568269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26).
    Danks MK; Yalowich JC; Beck WT
    Cancer Res; 1987 Mar; 47(5):1297-301. PubMed ID: 3469013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced formation of lesions in the DNA of a multidrug-resistant L1210 subline selected for teniposide resistance.
    Roberts DW; Foglesong PD; Parganas E; Wiggins L
    Cancer Chemother Pharmacol; 1989; 23(3):161-8. PubMed ID: 2538249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of drug disposition kinetics on cellular transport of the antineoplastic agent VM-26.
    Allen L
    Drug Metab Rev; 1978; 8(1):119-35. PubMed ID: 720213
    [No Abstract]   [Full Text] [Related]  

  • 7. Time dependence of [3H]-vincristine accumulation by L1210 mouse leukemic cells. Effect of P-glycoprotein overexpression.
    Breier A; Stefanková Z; Barancík M; Tribulová N
    Gen Physiol Biophys; 1994 Aug; 13(4):287-98. PubMed ID: 7890145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo.
    Sirotnak FM; Moccio DM; Kelleher LE; Goutas LJ
    Cancer Res; 1981 Nov; 41(11 Pt 1):4447-52. PubMed ID: 7306968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of 1-beta-D-arabinofuranosylcytosine transport and net accumulation by teniposide and etoposide in Ehrlich ascites cells and human leukemic blasts.
    White JC; Hines LH; Rathmell JP
    Cancer Res; 1985 Jul; 45(7):3070-5. PubMed ID: 4005845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
    Chen M; Beck WT
    Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
    Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of high-dose teniposide.
    Holthuis JJ; de Vries LG; Postmus PE; van Oort WW; Verleun H; Hulshoff A; Sleijfer DT; Mulder NH
    Cancer Treat Rep; 1987 Jun; 71(6):599-603. PubMed ID: 3581097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of uptake and binding of two epipodophyllotoxin glucopyranosides, 4'-demethyl epipodophyllotoxin thenylidene-beta-D-glucoside and 4'-demethyl epipodophyllotoxin ethylidene-beta-D-glucoside, in the L1210 leukemia cell.
    Allen LM
    Cancer Res; 1978 Aug; 38(8):2549-54. PubMed ID: 667850
    [No Abstract]   [Full Text] [Related]  

  • 14. Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity.
    Kerrigan D; Pommier Y; Kohn KW
    NCI Monogr; 1987; (4):117-21. PubMed ID: 3041238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of cytotoxicity of VM-26 and VP-16-213 on L1210 leukemia and hematopoietic stem cells.
    Vietti TJ; Valeriote FA; Kalish R; Coulter D
    Cancer Treat Rep; 1978 Sep; 62(9):1313-20. PubMed ID: 688275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of sorcin with drug resistance in L1210 cells.
    Roberts D; Meyers MB; Biedler JL; Wiggins LG
    Cancer Chemother Pharmacol; 1989; 23(1):19-25. PubMed ID: 2909286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the anticancer agent VM-26 on hexose uptake in Ehrlich cells.
    Wright SE; White JC
    Cancer Biochem Biophys; 1989 May; 10(3):185-96. PubMed ID: 2776116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential tumor immunogenicity of L1210 and its sublines. I. Effect of an increased antigen density on tumor cell surfaces on primary B cell responses in vitro.
    Fuji H; Mihich E; Pressman D
    J Immunol; 1977 Sep; 119(3):983-6. PubMed ID: 330761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical correlates of responsiveness and collateral sensitivity of some methotrexate-resistant murine tumors to the lipophilic antifolate, metoprine.
    Sirotnak FM; Moccio DM; Goutas LJ; Kelleher LE; Montgomery JA
    Cancer Res; 1982 Mar; 42(3):924-8. PubMed ID: 7059991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of murine leukemia antigen on L1210 parental and drug-resistant sublines.
    Strzadala L; Opolski A; Radzikowski C; Mihich E
    Cancer Res; 1981 Dec; 41(12 Pt 1):4934-7. PubMed ID: 7306993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.